Article
Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.
Nature immunology - 1 Jul 2021
Jacquelot Nicolas, Seillet Cyril, Wang Minyu, Pizzolla Angela, Liao Yang, Hediyeh-Zadeh Soroor, Grisaru-Tal Sharon, Louis Cynthia, Huang Qiutong, Schreuder Jaring, Souza-Fonseca-Guimaraes Fernando, de Graaf Carolyn A, Thia Kevin, Macdonald Sean, Camilleri Mary, Luong Kylie, Zhang Shengbo, Chopin Michael, Molden-Hauer Tristan, Nutt Stephen L, Umansky Viktor, Ciric Bogoljub, Groom Joanna R, Foster Paul S, Hansbro Philip M, McKenzie Andrew N J, Gray Daniel H D, Behren Andreas, Cebon Jonathan, Vivier Eric, Wicks Ian P, Trapani Joseph A, Munitz Ariel, Davis Melissa J, Shi Wei, Neeson Paul J, Belz Gabrielle T
Abstract excerpt
Group 2 innate lymphoid cells (ILC2s) are essential to maintain tissue homeostasis. In cancer, ILC2s can harbor both pro-tumorigenic and anti-tumorigenic functions, but we know little about their underlying mechanisms or whether they could be clinically relevant or targeted to improve patient outcomes. Here, we found that high ILC2 infiltration in human melanoma was associated with a good clinical prognosis....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.